Chronic helminth infection does not impair immune response to malaria transmission blocking vaccine Pfs230D1-EPA/Alhydrogel® in mice

Camila H. Coelho a,1, Pedro Henrique Gazzinelli-Guimaraes b,1, Jennifer Howard a, Emma Barnafo a, Nada A.H. Alania a, Olga Muratova a, Ashley McCormack a, Emily Kelhnofer a, Joseph F. Urban Jr. c, David L. Naruma a, Charles Anderson a, Jean Langhorned, Thomas B. Nutman b,2, Patrick E. Duffy a,⇑,2

a Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, USA
b Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
c US Department of Agriculture, Agricultural Research Service, Beltsville Human Nutrition Research Center, Diet, Genomic and Immunology Laboratory, Beltsville, MD, USA
d The Francis Crick Institute, London, UK

⇑Corresponding author at: Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5640 Fishers Lane, Room 1111, Rockville, MD 20852, USA.
E-mail address: Patrick.duffy@nih.gov (P.E. Duffy).
1 These authors contributed equally to this work.
2 These authors also contributed equally to this work.

A R T I C L E   I N F O

Article history:
Received 17 October 2018
Received in revised form 8 January 2019
Accepted 9 January 2019
Available online 23 January 2019

Keywords:
Malaria transmission blocking vaccine
H. polygyrus bakeri
Pfs230
P. falciparum
Helminth intestinal infection
Immunoregulation

A B S T R A C T

Introduction: Malaria transmission blocking vaccines (TBV) are innovative approaches that aim to induce immunity in humans against Plasmodium during mosquito stage, neutralizing the capacity of the infected vectors to transmit malaria. Pfs230D1-EPA/Alhydrogel®, a promising protein-protein conjugate malaria TBV, is currently being tested in human clinical trials in areas where P. falciparum malaria is coendemic with helminth parasites. Helminths are complex metazoans that share the master capacity to downregulate the host immune response towards themselves and also to bystander antigens, including vaccines. However, it is not known whether the activity of a protein-based malaria TBV may be affected by a chronic helminth infection.

Methods: Using an experimental murine model for a chronic helminth infection (Heligmosomoides polygyrus bakeri - Hpb), we evaluated whether prior infection alters the activity of Pfs230D1-EPA/Alhydrogel® TBV in mice.

Results: After establishment of a chronic infection, characterized by a marked increase of parasite antigen-specific IgG1, IgA and IgE antibody responses, concomitant with an increase of systemic IL-10, IL-5 and IL-6 levels, the Hpb-infected mice were immunized with Pfs230D1-EPA/Alhydrogel® and the vaccine-specific immune response was compared with that in non-infected immunized mice. TBV immunizations induced an elevated vaccine specific-antibody response, however Pfs230D1 specific-IgG levels were similar between infected and uninfected mice at days 15, 25 and 35 post-vaccination. Absolute numbers of Pfs230D1-activated B cells generated in response to the vaccine were also similar among the vaccinated groups. Finally, vaccine activity assessed by reduction of oocyst number in P. falciparum infected mosquitoes was similar between Hpb-infected and immunized mice with non-infected immunized mice.

Conclusion: Pfs230D1-EPA/Alhydrogel® efficacy is not impaired by a chronic helminth infection in mice. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

1. Introduction

To eradicate malaria, novel tools must integrate with existing approaches to reduce parasite transmission. One promising potential tool is a transmission-blocking vaccine (TBV), which aims to halt transmission by inducing antibodies targeting antigens expressed by the parasite in the mosquito host [5,32]. Pfs230, a protein present on the surface of Plasmodium falciparum gametes, is a leading candidate for a TBV.

Recently, a recombinant form of the first 6-cysteine rich domain of Pfs230 (domain 1, D1) was produced with the quality characteristics and quantity suitable for human clinical trials using the Pichia pastoris expression system [14]. In order to enhance immunogenicity, the ~20 kDa recombinant Pfs230D1 protein was chemically conjugated to a carrier protein (ExoProtein A, EPA)
and formulated in an adjuvant (Alhydrogel®). This vaccine candidate is currently in clinical trials in endemic areas [6].

Malaria-affected areas are often co-endemic with helminth parasite infections. Helminths belong to multiple taxonomic groups, but collectively they share the capacity to downregulate the parasite-directed host immune response [12,22,16,10]. During chronic infection, helminths modulate immune responses to bystander pathogens [17,2], and to some vaccine antigens [24,7].

The cytokine response to most helminth parasites (including the gastrointestinal nematode parasites) is characteristically both Th2- and IL10-dominated; the IL-10 response appears to derive from both adaptive (αTreg) and natural T regulatory cells (nTreg) [33,18]. These prototypical responses driven by helminths or helminth-derived molecules have been shown to alter the responses to some types of vaccines [26,1], though this is not a universal finding [9,30].

To date, few studies have examined whether a malaria TBV can be modulated by infection with intestinal helminth parasites. It has been recently suggested that Heligmosomoides polygyrus bakeri (Hpb) infection impairs the immunogenicity of a Plasmodium falciparum (Pfs25) DNA TBV, although this infection did not impair immunity to irradiated sporozoites [21].

Hpb is a natural intestinal parasite of mice, capable of establishing long-term chronic infections in many strains of mice which is ideally suited for lengthy immunization studies. During the infection, Hpb induces a markedly polarized early Th2 response characterized by increased IL-4, IL-13 and IgE production [23]. However, this persistent type 2 response shifts to long-lasting chronic infection, characterized by a strong regulatory response with expanded frequency of regulatory T cells and production of IL-10, peaking at day 28 post-infection [8]. At this stage of infection, the ability of Hpb to down-modulate responses to unrelated bystander antigens, including vaccine candidates, has been extensively demonstrated [31,27,25,29,21].

In this context, we used the mouse model of intestinal infection with Hpb to assess whether transmission-blocking immunity induced by Pfs230D1-EPA/Alhydrogel® would be impaired by helminth infection. Our findings demonstrate that chronic Hpb infection does not affect antibody responses or transmission-blocking activity induced by Pfs230D1-EPA/Alhydrogel® immunization. This supports the feasibility of TBV use in areas where intestinal helminths and malaria are co-endemic.

2. Materials and methods

2.1. Ethics statement

All animals were infected, vaccinated and sampled according to protocols approved by the NIAID Animal Care and Use Committee (Protocol #LPD-6).

2.2. H. polygyrus bakeri infection in mice

For each experiment, 10 BALB/c mice per group (male, 6 weeks old, Taconic Farm, USA) were infected with 200 H. polygyrus bakeri (Hpb) infective larvae (L3) by oral gavage 28 days before the first dose of the Pfs230D1-EPA/Alhydrogel® vaccine. The confirmation of Hpb infection and intensity follow-up were determined by fecal egg counts at days 25, 53 and 63 post-infection using standard protocols [4].

2.3. H. polygyrus bakeri excretory/secretory (HES) antigen preparation

HES antigens from adult worms were prepared as described by Johnston et al. [13] with some minor modifications. Briefly, Hpb adult worms were isolated from the duodenum of BALB/c mice inoculated 14 days earlier with 200 infective 3rd stage larvae (L3). The worms were soaked and washed six times in Hanks’ Solution (supplemented with 5 U/ml penicillin and 5 μg/ml streptomycin) and then placed in RPMI 1640 culture media plus a standard antibiotic mixture of penicillin (5 U/ml), streptomycin (5 μg/ml) and gentamicin (1%), distributed at approximately 400 adult worms per 2 ml in 24-well culture plates for 1–2 weeks. HES-containing culture media were collected at intervals of twice per week, and then were pooled out and concentrated over a 3000 MWCO filter. The protein concentration was determined by Bradford assay and the HES were used for the ELISA assays to measure helminth specific antibody response.

2.4. Pfs230D1-EPA alhydrogel® vaccine preparation

Pfs230D1-EPA (lot MV-1721) is a conjugate produced by chemically cross-linking Pfs230D1, a highly purified recombinant protein corresponding to Pfs230 expressed by gametocytes and on gametes, to rEPA, a highly purified recombinant protein corresponding to a mutant and detoxified Exoprotein A from Pseudomonas aeruginosa. The conjugate Pfs230D1-EPA (MV-1721) is composed of 54.6% Pfs230D1 and 45.4% EPA and manufactured under current good manufacturing practice (cGMP) with methods developed at the Laboratory of Malaria Immunology and Vaccinology (LMIV), National Institute of Allergy and Infectious Diseases, National Institutes of Health as described previously [14].

Pfs230D1-EPA (MV-1721) was formulated by adding 8.2 μl of the vaccine aseptically to each of two sterile Wheaton glass vials containing a mixture of 359.8 μl of Phosphate Buffered Saline (PBS, 1X, Gibco Catalog #10010-023) and 32 μl of Alhydrogel® 2% (Aluminum Hydroxide Gel Adjuvant, Brenntag Biosector, Batch #5240, EXP Dec 2017, Aluminum content: 9.8 mg/mL). Mixing was done using a Rotamix Rotator (ATR model #10101) at 16–24 rpm for 60 min, at room temperature (RT). The final formulation was then stored at 2–8°C for approximately 24 h prior to use for immunization of the mice.

2.5. Mouse immunization with Pfs230D1-EPA/Alhydrogel

Mice were infected with H. polygyrus bakeri as described above at day −28. After 28 days of infection with Hpb, ten BALB/c mice were immunized intramuscularly in the leg, with 1 μg of Pfs230D1-EPA/Alhydrogel® in 50 μL of PBS using a “hubless” syringe. The vaccine immunization day was considered as day 0. The second dose was given 28 days after the first vaccine dose (day 28). On day 35, 7 days after the second dose, all mice were euthanized. Experiments were performed in two independent sets of infection and immunizations comprising 5 mice per group.

2.6. Sample collection

Retro-orbital blood was collected from mice at days 0, 15 and 25 of the study (Fig. 1). Stool samples were collected at days −25, 25 and 35. On day 35, mice were euthanized, exsanguinated, and spleens were removed for isolation of B cells.

2.7. Detection of Pfs230D1 antibody response in sera

Antibody responses to Pfs230D1 were measured using an enzyme-linked immunosorbent assay (ELISA). Immulon® 4HBX plates were coated with 1 μg/well of recombinant Pfs230D1. Plates were incubated overnight at 4°C and blocked with 320 μL of buffer containing 5% skim milk powder in Tris–buffered saline for 2 h at RT. Plates were washed with Tween-TBS. Samples (dilution 1:500) were added to antigen-coated wells in triplicate and incu-
bated for 2 h at RT. Plates were washed, then 100 μL of alkaline phosphatase labelled goat anti-mouse IgG, IgG1, IgG2a or IgG3 (KPL) were added and incubated for 2 h at RT. The plates were washed and a colorimetric substrate (p-nitrophenyl phosphate; Sigma) was added. Plates were read at absorbances of 450 nm and 550 nm on a multi-well reader (Molecular Devices).

2.8. Detection of anti-Hpb antibody response in sera

Antibody responses to Hpb were measured by ELISA. Immulon® 4HBX plates were coated with 1μg/well of Hpb adult worm excretory/secretory (HES) antigen. Plates were incubated overnight at 4 °C and, after washing, blocked with 200 μL of PBS-BSA 5% for 1 h at RT. Plates were washed six times with Tween-TBS. 50μL of mouse serum (1:500 for IgG1, IgG2, IgG3, 1:10 for IgE and IgA in PBS-BSA 1%) were added to antigen-coated wells in duplicate and incubated for 1 h at RT. Plates were washed and then incubated separately with biotinylated rat anti-mouse IgG1, IgG2, IgG3, IgE and IgA (BD Pharmingen) (1:250 in PBS-BSA 1%) were added to antigen-coated wells in duplicate and incubated for 1 h at RT. Plates were washed and incubated with 50 μL of streptavidin conjugated with HRP (1:200 in PBS-BSA 1%) for 30 min at RT. After washing, TBM-substrate was added (50 μL/well) and incubated for ten minutes in the dark. 25 μL of 2 N H₂SO₄ was used to stop the reaction and plates were read at absorbances of 450 nm and 550 nm on a plate reader (Molecular Devices).

2.9. Multiplex assay for sera cytokines

Twenty-five microliters of each mouse serum were used to determine levels of IL-5, IL-6, IL-10, IL-13, TNF-a and IFN-γ by magnetic beads using Luminex multiplex assay (Milliplex; Millipore) based on the manufacturer’s recommendations.

2.10. Isolation of Pfs230D1-specific B cells

For isolation of Pfs230D1-specific B cells from splenocytes, we developed a biotin-streptavidin tetramer prepared with Pfs230D1 recombinant protein expressed in Pichia pastoris [14]. Tetramer preparation was performed as previously described [28,11]. Briefly, Pfs230D1 protein was biotinylated (EZ-link Sulfo-NHS-LC-Biotin, Thermo Fisher) and bound to streptavidin previously conjugated with fluorochrome PE (Prozyme). A decoy tetramer was generated using BSA and the fluorochromes PE and DL-594, to assure reduction of unspecific bindings. Splenocytes were isolated and incubated with 1 μM decoy tetramer and PBS containing 10% FBS and Fc Block (anti-CD16/32 clone 2.AG2), to inhibit unspecific binding of Fc receptor expressing cells, for 5 min at room temperature in the dark. Then, Pfs230D1-PE tetramer at 1 μM was added to the tube and incubated at 4 °C protected from light for 20 min. Cells were washed with PBS containing 10% FBS and incubated with anti-PE magnetic beads (Miltenyi Biotec) for 20 min. Four mL of PBS were added, and the suspension was passed over magnetized LS columns for elution of Pfs230D1-PE specific cells.

2.11. Flow cytometry

After enrichment with PE and Decoy Tetramers, splenocytes were stained with Zombie Violet live/dead, Alexa Fluor 700 anti-Gr-1 (clone RB6-8C5), Alexa Fluor 700 anti-CD3 (clone 17A2), Alexa Fluor 700 anti-F4/80 (clone BM8), APC-Cy7 anti-B220 (RA3-6B2), PE-Cy7 CD19 (clone 6D5) and PerCP/Cy5.5 anti GL7 (clone GL7) conjugated antibodies from Biolegend. Pfs230D1-specific B cells were gated and non-Pfs230D1 B cells were excluded. Cells were analyzed using LSR II cytometer (BD Biosciences) and analysed using FlowJo V.10 (Tree Star).

2.12. Transmission reduction activity

Transmission reducing activity (TRA), determined by the reduction of P. falciparum oocyst burden in the mosquito midgut, was evaluated using standard membrane feeding assay (SMFA) [19]. Briefly, an in vitro 15-day culture of stage V P. falciparum gametocytes (NF54 line) was diluted with washed O+ RBCs and an AB+ serum pool (not heat-inactivated) from malaria-naïve volunteers (Interstate Blood Bank, Memphis, Tennessee) to achieve 0.07–0.9% concentration of Stage V gametocytes and a 50% hematocrit. For each sample, 200 μL of diluted culture was mixed with 60 μL of test sample (mouse serum pool diluted 1:2 with naïve AB+ human serum pool) and immediately fed to pre-starved (24–30 h) 3–8-day-old Anopheles stephensi (Nijmegen strain) mosquitoes using a Parafilm® membrane in a mosquito feeder, kept warm with a jacket with 40 °C circulating water. After feeding, mosquitoes were kept at 26 °C and 80% humidity conditions to allow parasites to develop. On Day 8 after the feed, mosquito midguts were dissected and stained with 0.05–0.1% mercuriochrome solution in water for at least 20 min. Infectivity was measured by counting oocysts in at least 20 mosquitoes per sample. Pre-vaccination serum pools from the same mice was used as negative control. Each sample was tested in two independent SMFAs, and the two TRA values were averaged to obtain a single subject level TRA for a given time point.
2.13. Statistical analyses

Analyses were performed using data from two independent experiments. Statistical analyses for Pfs230D1 IgG measurement, specific B cells quantification by flow cytometry, and SMFA were performed by One-way ANOVA and corrected for multiple comparisons. Data from cytokine levels and Hpb IgG measurements were analysed using the Kruskal-Wallis test followed by Dunn’s multiple comparisons test. Parasite quantification in the stool samples was analysed by the Mann-Whitney test.

3. Results

To investigate if chronic helminth infection could impair the immunogenicity and/or efficacy of a malaria TBV, we infected BALB/c mice with Hpb L3 by gavage and 28 days later immunized them intramuscularly with two doses of Pfs230D1-EPA/Alhydrogel® (Fig. 1).

3.1. Hpb burden and anti-Hpb titers are maintained during vaccination with Pfs230D1-EPA/Alhydrogel®

We assessed the parasite burden and chronicity of the helminth infection by quantification of the Hpb eggs in the stool at day 25 (3 day prior to immunization), day 53 (25 days after TBV immunization) and day 63 post-infection (35 days after TBV administration). We also assayed Hpb-specific antibody production at day 63 post-infection. At all 3 time points, all animals from group 2 and group 4 were infected with similar egg counts (Fig. 2A–C). Before the euthanasia at day 63dpi the parasite burden in both infected groups were the same (Day 63; 43,236 ± 3644 eggs/g of stool vs. 40,264 ± 16,674 eggs/g of stool, p > 0.900) (Fig. 2C). Similarly, levels of Hpb-specific antibodies did not differ between the 2 Hpb-infected groups of mice. The Hpb-specific antibody response for the 2 Hpb-infected groups was characterized by a highly significant increase in the IgG1 but not IgG2a levels at day 63 post-infection, when compared with group 1 (naïve controls) and group

Fig. 2. Hpb Infection pattern was sustained after immunization. (a) Amount of Hpb eggs were similar in stools collected in animals infected only or both infected/vaccinated at days –3 (p = 0.574), 25 (p = 0.841) and 35 (p = 0.999). (b) ELISA optical density in response to Hpb antigen in sera. Sera collected at days –1, 15, 25 and 35 were used to assess IgG1, IgG2a, IgG3, IgE and IgA responses to H. polygyrus bakeri. Data are shown as mean ± SEM.
3.2. *H. polygyrus bakeri* infection does not alter antibody levels generated by Pfs230D1-EPA/Alhydrogel\(^{\text{c210}}\) vaccine

We next measured levels of Pfs230D1-specific IgG in all groups of mice (Fig. 3). Pfs230D1 antibody levels were similar between infected and uninfected mice at day 15 (67.6 ± 36.8 units vs 59.4 ± 47.1 units, p > 0.900) and at day 25 (168.2 ± 128.78 units vs. 161.3 ± 276.2 units, p > 0.900) post-vaccination. One week after the second vaccination (day 35), Pfs230D1 IgG titers were slightly higher in sera from Hpb-infected mice, but the difference was not statistically significant (2.469.5 ± 219.88 units vs. 1220.2 ± 1123.4 units, p = 0.1756). Pfs230D1-specific IgG titers were not detected in sera from unvaccinated mice (groups 1 and 2). Pfs230D1-specific IgG1, IgG2a and IgG3 levels were measured at day 35. IgG1 levels were similar between groups that were Hpb-infected and vaccinated and those only receiving the TBV (455.9 ± 268.8 vs. 540.2 ± 124.6p = 0.5862). IgG2a and IgG3 levels did not differ between immunized mice and the naïve group (p > 0.900), nor between Hpb-infected/vaccinated mice and those only vaccinated (p = 0.322). Overall, these results indicate that chronic Hpb infection does not impact the IgG response to Pfs230D1 immunization.

3.3. Pfs230D1 vaccination reduces serum levels of IL-10 but does not impact other cytokine profiles in Hpb-infected mice

At day 63 post inoculation (35 days following the first vaccination dose), Hpb infection induced a marked increase in IL-10 levels in the sera of group 2 compared to the uninfected animals (group 1; 42.9 ± 14.77 pg/mL vs. 2.4 ± 2.2 pg/mL, p = 0.042) or the uninfected but Pfs230-vaccinated animals (group 3; 10.1 ± 6.8 pg/mL). Interestingly, IL-10 levels did not increase in the animals of group 4 (Hpb-infected and Pfs230D1-vaccinated mice; 11.9 ± 6.9 pg/mL) (Fig. 4A), as compared with group 2. Serum levels of IL-6 increased in both Hpb-infected group 2 (30.6 ± 7.9 pg/mL vs 7.3 ± 2.3 pg/mL, p = 0.001) and group 4 (18.4 ± 2.6 pg/mL vs 9.6 ± 4.2 pg/mL, p = 0.001).

---

3 (vaccinated but not Hpb-infected mice) (1.42 ± 0.04 OD and 1.45 ± 0.04 OD vs. 0.02 ± 0.01 OD and 0.01 ± 0.01 OD, p < 0.01, respectively) (Fig. 2D and E). No significant differences for IgG3 were seen among the four groups (Fig. 2F) and similar increases in IgA and IgE isotypes were observed in groups 2 and 4 compared to group 1 and 3 (Fig. 2G and H).
3.4. *H. polygyrus bakeri* infection does not affect the number of activated B cells produced in Pfs230D1-EPA/Alhydrogel\textsuperscript{16} vaccination

To further characterize humoral responses and investigate whether Hpb infection affects vaccine-induced B cell generation, specific Pfs230D1-B cells were enumerated at day 35, seven days after the second immunization (Supplementary Fig. 1). The frequency of Pfs230D1-specific B cells was not statistically different between Hpb-infected and -uninfected groups that received the vaccine (45.2 ± 14.9 cells vs. 46.1 ± 19.2, p = 0.992, respectively) (Fig. 5).

Supplementary data associated with this article can be found, in the online version, at https://doi.org/10.1016/j.vaccine.2019.01.027.

3.5. Chronic helminth infection does not impair the functional activity of transmission blocking vaccine Pfs230D1-EPA/Alhydrogel\textsuperscript{16}

SMFA was performed to evaluate transmission-reducing activity, defined as a reduction in the number of oocysts per mosquito (Fig. 6). Sera from mice that received only Pfs230D1 conferred 36.1\% TRA (range 23.1–58.7\%) while sera from Hpb-infected and immunized mice conferred 32.8\% TRA (range 23.2–37.8\%), not significantly different from each other (p = 0.985) but both significantly greater than sera from naïve mice (p = 0.026 and p = 0.042, respectively). Sera from Hpb-infected unvaccinated mice reduced oocyst transmission by 22\%, which was not significantly different from the naïve group.

4. Discussion

In the current study, we evaluated whether chronic intestinal helminth infection alters the activity of a promising malaria transmission blocking vaccine.
Among the many helminth parasites that elicit immunomodulatory responses, one of the best-studied models is the intestinal nematode *Heligmosomoides polygyrus* in mice [20,15]. We infected 6-week-old BALB/c mice with the intestinal nematode *H. polygyrus* (Hpb), and immunized the mice starting 28 days later with Pfs230D1-EPA/Alhydrogel®; a vaccine aimed at reducing transmission of malaria, currently in clinical trials in malaria-endemic areas. Antibody responses to Hpb and the helminth burden in stool were used to assess the establishment of chronic infection. Hpb-infected mice demonstrated marked increase of helminth antigen-specific IgG1, IgA and IgE but not IgG2a antibody responses after 9 weeks of infection, concomitant with an increase of systemic IL-10 and IL-6 levels. This persistent parasite-specific type-2 immune response is normally associated with establishment of chronic infection in primary challenges with Hpb [20,3,15].

Vaccine immunogenicity was characterized by production of Pfs230D1-specific activated B cells in the spleen and by antibody titers to Pfs230D1, while vaccine functional activity was assessed by SMFA. Numbers of Pfs230D1-specific B cells, antibody titers and TRA were all significantly higher in vaccinated compared to unvaccinated animals, demonstrating vaccine immunogenicity. Most relevant to this study, production of antigen-specific B cells, antibody titers against Pfs230D1, and TRA did not differ between helminth-infected and uninfected animals. This study used a submaximal vaccine dosage (~0.5 μg target antigen) in BALB/c mice based on dose ranging studies conducted in other mouse strains (manuscript in preparation), with the expectation that a submaximal response would be more sensitive to immunosuppression. Of note, this vaccine regimen yielded lower TRA levels in BALB/c mice versus levels we have seen for other mouse strains. These differences could be due to strain-specific differences in the immune response, or to the timing of blood sampling (collections on day 7 versus day 14, respectively, after boost). Nevertheless, our data demonstrate that the antibody activity induced by Pfs230D1-EPA was not impaired by Hpb infection, with similar TRA achieved in Hpb-infected and uninfected mice. Our data collectively demonstrate that the immunogenicity and functional activity of Pfs230D1-EPA/Alhydrogel® vaccine were not impaired by Hpb infection in BALB/c mice. This lends support to the notion that this protein-based malaria transmission blocking vaccine could be implemented in malaria-endemic areas where helminth co-infection is common.

**Author contributions**

CHC, JL and PHGG conceived the study, CHC, PHGG, EB, JL, JH, JFU, CA, TBN and PED designed the experiments. CHC, PHGG, JH, EB, NAHA, OM, AM, EK performed experiments. CHC, PHGG, JH, NAHA, OM analyzed data. CHC, PHGG, EB, JH, CA, NAHA, DN, AM, OM, JFU, JL, TBN and PED interpreted the data and wrote the manuscript.

**Competing interests**

The authors declare no competing interests.

**Acknowledgments**

This work was supported by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases, National Institutes of Health. Jean Langhorne is supported by the Francis Crick Institute which receives its core funding from the UK Medical Research Council, Cancer Research UK, and the Wellcome Trust (FC10101).

We thank Lynn Lambert, Sachy Orr-Gonzalez and Brandi Butler for animal euthanasia and sample collection. We thank J. Patrick Gorres for proof reading and editing the manuscript.

**References**

1. Apiwattanakul N, Thomas PG, Iverson AR, McCullers JA. Chronic helmith infections impair pneumococcal vaccine responses. Vaccine 2014;32 (42):5465–10.
2. Babii S, Nutman TB. Helminth-tuberculosis co-infection: an immunologic perspective. Trends Immunol 2016;37(9):597–607.
3. Ben-Smith A, Lammans DA, Behnke JM. The relative involvement of Th1 and Th2 associated immune responses in the expulsion of a primary infection of *Heligmosomoides polygyrus* and of differing response phenotype. J Helminthol 1997;27(2):133–46.
4. Camberis M, Le Gros G, Urban JF. Animal model of *Nippostrongylus brasiliensis* and *Heligmosomoides polygyrus*.Curr Protoc Immunol 2003 [Chapter 19: Unit 19.12].
5. Carter R. Transmission blocking malaria vaccines. Vaccine 2001;19(17–19):2309–14.
6. Coelho CH, Donohue-Young I, Zaidi I, Duffy PE. Advances in malaria vaccine development: report from the 2017 malaria vaccine symposium. NPJ Vacc 2017:2:34.
7. Cooper PJ, Espiell I, Paredes W, Guedarian RH, Nutman TB. Impaired tetanus-specific cellular and humoral responses following tetanus vaccination in human onchocerciasis: a possible role for interleukin-10. J Infect Dis 1998;178(4):1133–8.
8. Finney CA, Taylor MD, Wilson MS, Maizels RM. Expansion and activation of CD4+CD25+ regulatory T cells in *Heligmosomoides polygyrus* infection. Eur J Immunol 2007;37(7):1874–86.
9. Franzig FG, Rosada RS, Peres-Buzalaf C, Peruzzo FR, Rodrigues V, Ramos SG, et al. Helminth confection does not affect therapeutic effect of a DNA vaccine in mice harboring tuberculosis. PLoS Negl Trop Dis 2010;4(4):e700.
10. Gazzinelli-Guimaraes PH, Nutman TB. Helminth parasites and immunity regulation. F1000Res 7; 2018.
11. Hamilton JA, Li J, Wu Q, Yang P, Luo B, Li H, et al. General approach for tetramer-based identification of autologous recombinant B cells: characterization of La- and snRNP-reactive B cells in autoimmune BXD2 mice. J Immunol 2015;194(10):5022–34.
12. Harnett W, Harnett MM. Lymphocyte hyporesponsiveness during filarial nematode infection. Parasite Immunol 2008;30(9):447–53.
13. Johnston CJ, Robertson E, Harcus Y, Grainger JR, Oakley G, Smyth DJ, et al. Cultivation of *Heligmosomoides polygyrus*: an immunomodulatory nematode parasite and its secreted products. J Vis Exp 2015;98:e52412.
14. MacDonald NJ, Nguyen V, Shimp R, Reiter K, Herrera B, Burkhardt M, et al. Structural and immunological characterization of recombinant 6-cysteine domains of the *Plasmodium falciparum* sexual stage protein Pfs230. J Biol Chem 2016;291(38):19913–22.
15. Maizels RM, Hewlitt JP, Murray J, Harcus Y, Dayer B, Filby KL, et al. Immunogenicity and modulation of *Heligmosomoides polygyrus* infection. Exp Parasitol 2012;132(1):76–85.
16. Maizels RM, McSorley HJ. Regulation of the host immune system by helminth parasites. J Allergy Clin Immunol 2016;138(3):666–75.
17. Metenou S, Kovacs M, Dembele B, Coulibaly YI, Klion AD, Nutman TB. Interferon regulatory factor modulation underlies the bystander suppression of malaria antigen-driven IL-12 and IFN-gamma in *Plasmodium falciparum* co-infection. Eur J Immunol 2001;31:51–60.
18. Mitaure K, Deng B, Tullo G, Diouf A, Moretz SE, Locke E, et al. Helminth co-infection impairs the immunogenicity of a Plasmodium falciparum DNA vaccine, but not immunized sporozoites, in mice. Vaccine 2010;28(17):2917–23.
19. Nutman TB. Looking beyond the induction of Th2 responses to explain immunomodulation by helminths. Parasite Immunol 2015;37(6):304–13.
20. Reynolds LA, Filby RJ, Maizels RM. Immunity to the model intestinal helminth parasite *Heligmosomoides polygyrus*. Semin Immunopathol 2012;34(4):829–46.
21. Sabin EA, Araujo ML, Carvalho EM, Pearce JE. Impairment of tetanus toxoid-specific Th1-like immune responses in humans infected with *Schistosoma mansoni*. J Infect Dis 1996;173(1):69–101.
22. Setiawan T, Metwali A, Blum AM, Ince MN, Urban Jr JF, Elliott DE, et al. Interferon regulatory factor modulation underlies the bystander suppression of malaria antigen-driven IL-12 and IFN-gamma in *Plasmodium falciparum* co-infection. Eur J Immunol 2001;31:51–60.
23. Setiawan T, Metwali A, Blum AM, Ince MN, Urban Jr JF, Elliott DE, et al. Interferon regulatory factor modulation underlies the bystander suppression of malaria antigen-driven IL-12 and IFN-gamma in *Plasmodium falciparum* co-infection. Eur J Immunol 2001;31:51–60.
24. Sabin EA, Araujo ML, Carvalho EM, Pearce JE. Impairment of tetanus toxoid-specific Th1-like immune responses in humans infected with *Schistosoma mansoni*. J Infect Dis 1996;173(1):69–101.
25. Setiawan T, Metwali A, Blum AM, Ince MN, Urban Jr JF, Elliott DE, et al. Interferon regulatory factor modulation underlies the bystander suppression of malaria antigen-driven IL-12 and IFN-gamma in *Plasmodium falciparum* co-infection. Eur J Immunol 2001;31:51–60.
[27] Su Z, Segura M, Stevenson MM. Reduced protective efficacy of a blood-stage malaria vaccine by concurrent nematode infection. Infect Immun 2006;74(4):2138–44.

[28] Taylor JJ, Martinez RJ, Titcombe PJ, Barsness LO, Thomas SR, Zhang N, et al. Deletion and anergy of polyclonal B cells specific for ubiquitous membrane-bound self-antigen. J Exp Med 2012;209(11):2065–77.

[29] Urban Jr JF, Steenhard NR, Solano-Aguilar GI, Dawson HD, Iweala GI, Nagler CR, et al. Infection with parasitic nematodes confounds vaccination efficacy. Vet Parasitol 2007;148(1):14–20.

[30] Wajja A, Kizito D, Nalwanga B, Naivwoga A, Kabagenyi J, Kimuda S, et al. The effect of current Schistosoma mansoni infection on the immunogenicity of a candidate TB vaccine, MVA85A, in BCG-vaccinated adolescents: an open-label trial. PLoS Negl Trop Dis 2017;11(5):e0005440.

[31] Wilson MS, Taylor MD, Balic A, Finney CA, Lamb JR, Maizels RM. Suppression of allergic airway inflammation by helminth-induced regulatory T cells. J Exp Med 2005;202(9):1199–212.

[32] Wu Y, Sinden RE, Churcher TS, Tsuboi T, Yusibov V. Development of malaria transmission-blocking vaccines: from concept to product. Adv Parasitol 2015;89:109–52.

[33] Yazdanbakhsh M, Wahyuni S. The role of helminth infections in protection from atopic disorders. Curr Opin Allergy Clin Immunol 2005;5(5):386–91.